By analyzing existing basic indicators between I Mab and Collegium, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Collegium with a short position in I Mab. Check out our
pair correlation module for more information.
Let's begin by analyzing the assets.
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. I Mab has an asset utilization ratio of 1.57 percent. This suggests that the company is making $0.0157 for each dollar of assets. An increasing asset utilization means that I-Mab is more efficient with each dollar of assets it utilizes for everyday operations.
Please consider monitoring I Mab on a daily basis if you are holding a position in it. I Mab is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as I Mab stock to be traded above the $1 level to remain listed. If I Mab stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
I Mab
financial leverage refers to using borrowed capital as a funding source to finance I Mab ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. I Mab financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to I Mab's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of I Mab's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between I Mab's total debt and its cash.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Revenue Breakdown
Lets now check I Mab revenue. Based on the latest financial disclosure, I-Mab reported 88.03
M of revenue. This is 98.85% lower than that of the Biotechnology sector and 88.15% lower than that of the
Health Care industry. The revenue for all United States stocks is 99.07% higher than that of I Mab. As for Collegium Pharmaceutical we see revenue of 276.87
M, which is 62.73% lower than that of the Health Care
| IMAB | 88.03 Million | 7.95 |
| Sector | 742.91 Million | 67.06 |
| COLL | 276.87 Million | 24.99 |
Our perspective of the current I Mab rise
The sortino ratio is down to 0.11 as of today. I-Mab is displaying above-average volatility over the selected time horizon. Investors should scrutinize I-Mab independently to ensure intended market timing strategies are aligned with expectations about I Mab volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure I Mab's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact I Mab's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Our Bottom Line On I-Mab
Whereas some companies within the biotechnology industry are still a little expensive, even after the recent corrections, I Mab may offer a potential longer-term growth to investors. With a somewhat neutral outlook on your 90 days horizon, it may be better to hold off any trading activity and neither pick up new shares of I Mab nor exit your existing holdings in the Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to I Mab.
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of I Mab. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com